Yarrow Bioscience
YARW
37 hedge funds and large institutions have $3.25M invested in Yarrow Bioscience in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 8 closing their positions.
0.96% less ownership
Funds ownership: 15.42% → 14.46% (-0.96%)
10% less funds holding
Funds holding: 41 → 37 (-4)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
41% less capital inflows, than outflows
Capital inflows: $323K | Capital outflows: $551K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$150K |
| 2 |
Two Sigma Securities
New York
|
+$59.6K |
| 3 |
Cetera Advisor Networks
El Segundo,
California
|
+$53.7K |
| 4 |
Virtu Financial
New York
|
+$18.9K |
| 5 |
Citigroup
New York
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSA Capital Partners
London,
United Kingdom
|
-$154K |
| 2 |
Bailard
Foster City,
California
|
-$91K |
| 3 |
Millennium Management
New York
|
-$88.1K |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$65K |
| 5 |
BlackRock
New York
|
-$52.8K |
YARW Hedge Fund Activity: Q2 2022 in Review
37 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q2 2022, worth a combined $3.25M — down 42% from $5.63M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of YARW and 5 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $150K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $154K sold.
- 37 institutional investors held Yarrow Bioscience (YARW) as of Q2 2022, down from 41 in Q1 2022.
- Funds reported $3.25M of Yarrow Bioscience stock for Q2 2022, down 42% quarter-over-quarter.
- 5 funds opened new Yarrow Bioscience positions in Q2 2022 and 8 closed out, a net change of -3 holders.
- The largest Yarrow Bioscience buyer in Q2 2022 was Vanguard Group, an estimated $150K added.
- The largest Yarrow Bioscience seller in Q2 2022 was GSA Capital Partners, an estimated $154K sold.
Based on aggregated 13F filings for Q2 2022.